Journal of Inherited Metabolic Disease

, Volume 33, Supplement 2, pp 205–210 | Cite as

Expanded newborn screening: reducing harm, assessing benefit

  • Bridget WilckenEmail author
Newborn Screening


Achieving the goals of newborn screening is, as for any screening, a balancing act: getting the maximum benefit from screening while producing the minimum harm. The advent of “expanded” newborn screening, with a large number of disorders detectable using a single test, has also posed problems, not new, but now more obvious. One is the finding of many more cases by screening, the extra cases being largely patients who have attenuated phenotypes and may remain asymptomatic for many years, even throughout life. These may or may not require active management in the short term, but do need lifelong awareness. Additionally, disorders have been included that are now thought benign or largely so. Babies risk being unnecessarily medicalized. Assessing outcome has also proved difficult because of the rarity of some disorders and the impracticality of randomized controlled trials. The requirements for valid studies include the need for case definitions, comparable comparison groups and probably assessment on a whole-population basis. An Australia-wide study of tandem mass spectrometry newborn screening involving 2 million screened and unscreened babies has demonstrated benefits overall to screened patients at age 6 years. The study was too small to provide conclusions for individual disorders other than for medium-chain acyl-CoA dehydrogenase deficiency.


Newborn Screening Congenital Hypothyroidism Newborn Screening Programme Minimum Harm Fatty Acid Oxidation Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Arnold GL, Koeberl DD, Matern D et al (2008) A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab 93:363–370CrossRefPubMedGoogle Scholar
  2. Arnold GL, Van Hove J, Freedenberg D et al (2009) Clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96:85–90CrossRefPubMedGoogle Scholar
  3. Barashnev JI, Nikolayeva EA, Klembovsky AI (1988) Histidinaemia: screening, diagnosis, clinical picture, therapy. Acta Paediatr Hung 29:343–351PubMedGoogle Scholar
  4. Berning C, Bieger I, Pauli S et al (2008) Investigation of citrullinemia type I variants by in vitro expression studies. Hum Mutat 29:1222–1227CrossRefPubMedGoogle Scholar
  5. Danks DM, Bartholomé K, Clayton B et al (1978) Malignant hyperphenylalaninaemia—the current status. J Inherit Metab Dis 1:49–53CrossRefPubMedGoogle Scholar
  6. Dimmock DP, Trapane P, Feigenbaum A et al (2008) The role of molecular testing and enzyme analysis in the management of hypomorphic citrullinemia. Am J Med Genet 146A:2885–2890CrossRefPubMedGoogle Scholar
  7. Engel K, Höhne W, Häberle J (2009) Mutations and polymorphisms in the human argininosuccinate synthetase (ASS1) gene. Hum Mutat 30:300–307CrossRefPubMedGoogle Scholar
  8. Gao HZ, Kobayashi K, Tabata A et al (2003) Identification of 16 novel mutations in the argininosuccinate synthetase gene and genotype-phenotype correlation in 38 classical citrullinemia patients. Hum Mutat 22:24–34CrossRefPubMedGoogle Scholar
  9. Ghadimi H, Partington MW (1967) Salient features of histidinemia. Am J Dis Child 113:83–87PubMedGoogle Scholar
  10. Gregersen N, Andresen BS, Pedersen CB, Olsen RK, Corydon TJ, Bross P (2008) Mitochondrial fatty acid oxidation defects-remaining challenges. J Inherit Metab Dis 31:643–657CrossRefPubMedGoogle Scholar
  11. Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ (2006) The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med 8:205–212CrossRefPubMedGoogle Scholar
  12. Häberle J, Pauli S, Schmidt E, Schulze-Eilfing B, Berning C, Koch HG (2003) Mild citrullinemia in Caucasians is an allelic variant of argininosuccinate synthetase deficiency (citrullinemia type 1). Mol Genet Metab 80:302–306CrossRefPubMedGoogle Scholar
  13. Häberle J, Vilaseca MA, Meli C et al (2010) First manifestation of citrullinemia type I as differential diagnosis to postpartum psychosis in the puerperal period. Eur J Obstet Gynecol Reprod Biol, in pressGoogle Scholar
  14. Hewlett J, Waisbren SE (2006) A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J Inherit Metab Dis 29:677–682CrossRefPubMedGoogle Scholar
  15. Ito S, Kurasawa G, Yamamoto K et al (2004) A pregnant patient with fulminant hepatic failure was found to carry a novel missense mutation in the argininosuccinate synthetase gene. J Gastroenterol 39:1115–1117CrossRefPubMedGoogle Scholar
  16. Jethva R, Bennett MJ, Vockley J (2008) Short-chain acyl-coenzyme A dehydrogenase deficiency. Mol Genet Metab 95:195–200CrossRefPubMedGoogle Scholar
  17. Kurasawa G, Shiotsuka S, Nakajo J, Nagao M, Ohisi M, Aida T, Tanaka T (1998) A case report of citrullinemia induced by pregnancy. Nissanpu Kantoren Kaihou 35:3–7Google Scholar
  18. La Franchi S (2010) Newborn screening strategies for congenital hypothyroidism: an update. J Inherit Metab Dis, [this issue]Google Scholar
  19. Lam WK, Cleary MA, Wraith JE, Walter JH (1996) Histidinaemia: a benign metabolic disorder. Arch Dis Child 74:343–346CrossRefPubMedGoogle Scholar
  20. Lenke RR, Levy HL (1980) Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. N Engl J Med 303:1202–1208CrossRefPubMedGoogle Scholar
  21. Lipstein EA, Perrin JM, Waisbren SE, Prosser LA (2009) Impact of false-positive newborn metabolic screening results on early health care utilization. Genet Med 11:716–721CrossRefPubMedGoogle Scholar
  22. Ly TB, Peters V, Gibson KM et al (2003) Mutations in the AUH gene cause 3-methylglutaconic aciduria type I. Hum Mutat 21:401–407CrossRefPubMedGoogle Scholar
  23. Marsden DL (2009) Commentary on a Delphi clinical practice protocol for the diagnosis and management of very long chain acyl-CoA dehydrogenase deficiency by Arnold et al. Mol Genet Metab 96:81–82CrossRefPubMedGoogle Scholar
  24. Nennstiel-Ratzel U, Arenz S, Maier EM et al (2005) Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c.985A>G identified by neonatal screening. Mol Genet Metab 85:157–159CrossRefPubMedGoogle Scholar
  25. Neville BG, Bentovim A, Clayton BE, Shepherd J (1972) Histidinaemia. Study of relation between clinical and biological findings in 7 subjects. Arch Dis Child 47(252):190–200CrossRefPubMedGoogle Scholar
  26. Pedersen CB, Kølvraa S, Kølvraa A et al (2008) The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. Hum Genet 124:43–56CrossRefPubMedGoogle Scholar
  27. Popkin JS, Clow CL, Scriver CR, Grove J (1974) Is hereditary histidinaemia harmful? Lancet 1(7860):721–722CrossRefPubMedGoogle Scholar
  28. Prosser LA, Ladapo JA, Rusinak D, Waisbren SE (2008) Parental tolerance of false-positive newborn screening results. Arch Pediatr Adolesc Med 162:870–876CrossRefPubMedGoogle Scholar
  29. Sander J, Janzen N, Sander S et al (2003) Neonatal screening for citrullinaemia. Eur J Pediatr 162:417–420PubMedGoogle Scholar
  30. Sass JO, Ensenauer R, Röschinger W et al (2008) 2-Methylbutyryl-coenzyme A dehydrogenase deficiency: functional and molecular studies on a defect in isoleucine catabolism. Mol Genet Metab 93:30–35CrossRefPubMedGoogle Scholar
  31. Spiekerkoetter U, Lindner M, Santer R et al (2009) Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 32:498–505CrossRefPubMedGoogle Scholar
  32. van Maldegem BT, Duran M, Wanders RJ et al (2006) Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. JAMA 296:943–952CrossRefPubMedGoogle Scholar
  33. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) STROBE initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335(7624):806–808CrossRefGoogle Scholar
  34. Widhalm K, Virmani K (1994) Long-term follow-up of 58 patients with histidinemia treated with a histidine-restricted diet: no effect of therapy. Pediatrics 94:861–866PubMedGoogle Scholar
  35. Wilcken B (2008) The consequences of extended newborn screening programmes: do we know who needs treatment? J Inherit Metab Dis 31:173–177CrossRefGoogle Scholar
  36. Wilcken B (2010) Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis, in pressGoogle Scholar
  37. Wilcken B, Wiley V, Hammond J, Carpenter K (2003) Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 348:2304–2312CrossRefPubMedGoogle Scholar
  38. Wilcken B, Haas M, Joy P et al (2009) Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 124:e241–e248CrossRefPubMedGoogle Scholar
  39. Woods WG, Gao RN, Shuster JJ et al (2002) Screening of infants and mortality due to neuroblastoma. N Engl J Med 346:1041–1046CrossRefPubMedGoogle Scholar
  40. Wortmann SB, Kremer BPH, Graham A et al (2010) 3-Methylglutaconic aciduria type I redefined; a syndrome with late onset leukoencephalopathy. Neurology, in pressGoogle Scholar

Copyright information

© SSIEM and Springer 2010

Authors and Affiliations

  1. 1.Biochemical Genetics and Newborn ScreeningThe Children’s Hospital at WestmeadWestmeadAustralia
  2. 2.The University of SydneySydneyAustralia

Personalised recommendations